teaser
An American company has claimed a new four-in-one treatment for HIV can reduce patients’ viral load.
Biopharmaceutical company, Gilead Sciences Inc, is currently testing the single-tablet treatment, which consists of elvitegravir, cobicistat and Truvada.
The drug, which includes emtricitabine and tenofovir disoproxil fumarate, successfully reduced the viral load in patients during a midstage study.
Gilead already produces three-in-one HIV treatment Atripla. The new findings were presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston on Monday 13 September.
Copyright Press Association 2010
Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
